Decibel Therapeutics, Inc.
https://www.decibeltx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Decibel Therapeutics, Inc.
Regeneron Strikes A CHORD With Deafness Gene Therapy
A very early success with a gene therapy for a rare form of deafness puts Regeneron ahead of Lilly and Sensorion.
Regeneron Buys Partner Decibel Outright
Deal Snapshot: Regeneron will buy Decibel for about $109m, plus a contingent value right linked to milestones related to gene therapy programs for hearing loss.
Finance Watch: SPAC Spree To Continue ‘For Foreseeable Future’
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
Finance Watch: Ten IPOs In Three Days Raise $1.9bn
IPO Edition: Sana leads the group with a $587.5m initial public offering, while Immunocore and Bolt follow with $200m-plus IPOs. The 10 newly public companies generated a 43.3% average return on 8 Feb.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice